We are live on ! Find out more
BIAFW icon

bioAffinity Technologies
BIAFW

3 hedge funds and large institutions have $47.1K invested in bioAffinity Technologies in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $44.2K → $47.1K (+$2.92K)

12.9% less ownership

Funds ownership: 21.24% → 8.34% (-13%)

25% less funds holding

Funds holding: 4 → 3 (-1)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CS
Clear Street
New York
+$28

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$26.5K
2
Citadel Advisors
Citadel Advisors
Florida
-$252
3
UBS Group
UBS Group
Switzerland
-$128

BIAFW Hedge Fund Activity: Q3 2025 in Review

3 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAFW) for Q3 2025, worth a combined $47.1K — up 6.6% from $44.2K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of BIAFW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was Clear Street, adding an estimated $28. The largest seller was Armistice Capital, exiting entirely with an estimated $26.5K sold.

  • 3 institutional investors held bioAffinity Technologies (BIAFW) as of Q3 2025, down from 4 in Q2 2025.
  • Funds reported $47.1K of bioAffinity Technologies stock for Q3 2025, up 6.6% quarter-over-quarter.
  • 0 funds opened new bioAffinity Technologies positions in Q3 2025 and 1 closed out, a net change of -1 holder.
  • The largest bioAffinity Technologies buyer in Q3 2025 was Clear Street, an estimated $28 added.
  • The largest bioAffinity Technologies seller in Q3 2025 was Armistice Capital, an estimated $26.5K sold.

Based on aggregated 13F filings for Q3 2025.